$AWH
Aspira Women's Health Inc.

2021 Q4 Form 10-Q Financial Statement

#000092661721000079 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $1.851M $1.666M $1.239M
YoY Change 27.66% 34.46% -3.58%
Cost Of Revenue $837.0K $917.0K $807.0K
YoY Change -31.39% 13.63% -14.96%
Gross Profit $1.014M $749.0K $432.0K
YoY Change 340.87% 73.38% 28.57%
Gross Profit Margin 54.78% 44.96% 34.87%
Selling, General & Admin $8.507M $8.922M $4.118M
YoY Change 52.73% 116.66% 7.07%
% of Gross Profit 838.95% 1191.19% 953.24%
Research & Development $1.453M $1.518M $595.0K
YoY Change 99.04% 155.13% 75.0%
% of Gross Profit 143.29% 202.67% 137.73%
Depreciation & Amortization $64.00K $66.00K $70.00K
YoY Change -28.89% -5.71% 16.67%
% of Gross Profit 6.31% 8.81% 16.2%
Operating Expenses $9.960M $10.44M $4.713M
YoY Change 58.1% 121.51% 12.59%
Operating Profit -$8.946M -$9.691M -$4.281M
YoY Change 47.38% 126.37% 11.19%
Interest Expense -$13.00K -$14.00K $10.00K
YoY Change -240.0% -66.67%
% of Operating Profit
Other Income/Expense, Net -$2.000K -$2.000K -$11.00K
YoY Change -81.82% 175.0%
Pretax Income -$8.961M -$9.707M -$4.290M
YoY Change 47.38% 126.27% 12.3%
Income Tax
% Of Pretax Income
Net Earnings -$8.961M -$9.707M -$4.287M
YoY Change 47.38% 126.43% 12.23%
Net Earnings / Revenue -484.12% -582.65% -346.0%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$79.92K -$86.61K -$41.57K
COMMON SHARES
Basic Shares Outstanding 112.1M 112.1M 103.8M
Diluted Shares Outstanding 112.1M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.18M $44.87M $18.80M
YoY Change 123.98% 138.67% 28.77%
Cash & Equivalents $37.18M $44.87M $18.84M
Short-Term Investments
Other Short-Term Assets $1.624M $1.078M $500.0K
YoY Change 47.64% 115.6% 25.0%
Inventory $174.0K $137.0K $0.00
Prepaid Expenses
Receivables $1.027M $1.103M $848.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $40.01M $47.19M $20.25M
YoY Change 115.05% 133.02% 26.17%
LONG-TERM ASSETS
Property, Plant & Equipment $464.0K $498.0K $1.000M
YoY Change -20.41% -50.2% 150.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $14.00K $0.00 $0.00
YoY Change 7.69% -100.0%
Total Long-Term Assets $1.074M $859.0K $1.014M
YoY Change 7.19% -15.29% 109.94%
TOTAL ASSETS
Total Short-Term Assets $40.01M $47.19M $20.25M
Total Long-Term Assets $1.074M $859.0K $1.014M
Total Assets $41.08M $48.05M $21.27M
YoY Change 109.53% 125.94% 28.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.501M $1.155M $1.315M
YoY Change 36.08% -12.17% 46.11%
Accrued Expenses $5.299M $4.998M $2.815M
YoY Change 46.46% 77.55% 17.15%
Deferred Revenue
YoY Change
Short-Term Debt $779.0K $0.00 $476.0K
YoY Change 27.5% -100.0% 138.0%
Long-Term Debt Due $201.0K $200.0K
YoY Change -68.84%
Total Short-Term Liabilities $7.840M $6.409M $4.600M
YoY Change 30.67% 39.33% 30.05%
LONG-TERM LIABILITIES
Long-Term Debt $2.718M $2.768M $1.700M
YoY Change -21.83% 62.82% 48.08%
Other Long-Term Liabilities $349.0K $366.0K $400.0K
YoY Change -12.75% -8.5% 1804.76%
Total Long-Term Liabilities $2.718M $2.768M $2.100M
YoY Change -21.83% 31.81% 79.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.840M $6.409M $4.600M
Total Long-Term Liabilities $2.718M $2.768M $2.100M
Total Liabilities $10.91M $9.543M $6.700M
YoY Change 10.33% 42.43% 42.37%
SHAREHOLDERS EQUITY
Retained Earnings -$471.7M -$462.8M -$434.0M
YoY Change 7.19% 6.63% 3.63%
Common Stock $112.0K $112.0K
YoY Change 6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.17M $38.50M $14.55M
YoY Change
Total Liabilities & Shareholders Equity $41.08M $48.05M $21.30M
YoY Change 109.53% 125.57% 28.83%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$8.961M -$9.707M -$4.287M
YoY Change 47.38% 126.43% 12.23%
Depreciation, Depletion And Amortization $64.00K $66.00K $70.00K
YoY Change -28.89% -5.71% 16.67%
Cash From Operating Activities -$7.649M -$8.001M -$3.070M
YoY Change 61.03% 160.62% -10.76%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K -$18.00K -$150.0K
YoY Change -86.36% -88.0% 275.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$18.00K -$150.0K
YoY Change -86.36% -88.0% 275.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -11.00K 146.0K 11.11M
YoY Change -100.4% -98.69% 472.68%
NET CHANGE
Cash From Operating Activities -7.649M -8.001M -3.070M
Cash From Investing Activities -30.00K -18.00K -150.0K
Cash From Financing Activities -11.00K 146.0K 11.11M
Net Change In Cash -7.690M -7.873M 7.890M
YoY Change 249.55% -199.78% -612.34%
FREE CASH FLOW
Cash From Operating Activities -$7.649M -$8.001M -$3.070M
Capital Expenditures -$30.00K -$18.00K -$150.0K
Free Cash Flow -$7.619M -$7.983M -$2.920M
YoY Change 68.19% 173.39% -14.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0000926617
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34810
dei Entity Registrant Name
EntityRegistrantName
Aspira Women’s Health Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Building Three
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
519-0400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AWH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
112126549
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44870000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16631000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
250000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1103000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
865000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
828000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1077000
CY2021Q3 us-gaap Inventory Net
InventoryNet
137000
CY2020Q4 us-gaap Inventory Net
InventoryNet
30000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
47188000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18603000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
498000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
361000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
406000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000
CY2021Q3 us-gaap Assets
Assets
48047000
CY2020Q4 us-gaap Assets
Assets
19605000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1155000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1103000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4998000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3618000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
200000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
645000
CY2020Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
611000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6409000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6000000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2768000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3477000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
366000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
409000
CY2021Q3 us-gaap Liabilities
Liabilities
9543000
CY2020Q4 us-gaap Liabilities
Liabilities
9886000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9691000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440066000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
38504000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9719000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48047000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1518000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112100049
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112100049
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104619876
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104619876
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
112000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
105000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
501159000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
449680000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-462767000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19605000
CY2021Q3 us-gaap Revenues
Revenues
1666000
CY2020Q3 us-gaap Revenues
Revenues
1239000
us-gaap Revenues
Revenues
4961000
us-gaap Revenues
Revenues
3205000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
917000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
807000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2913000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2200000
CY2021Q3 us-gaap Gross Profit
GrossProfit
749000
CY2020Q3 us-gaap Gross Profit
GrossProfit
432000
us-gaap Gross Profit
GrossProfit
2048000
us-gaap Gross Profit
GrossProfit
1005000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
595000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3861000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1370000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5083000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2152000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12209000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6000000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3839000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1966000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9627000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5542000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
10440000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
4713000
us-gaap Operating Expenses
OperatingExpenses
25697000
us-gaap Operating Expenses
OperatingExpenses
12912000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
317000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47720000
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
489000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4281000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23649000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11907000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-35000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
983000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
69000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9707000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4287000
us-gaap Net Income Loss
NetIncomeLoss
-22701000
us-gaap Net Income Loss
NetIncomeLoss
-11824000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
112077133
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
103200612
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
110904824
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99555194
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9719000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5920000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
52325000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7074000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
304000
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
267000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1015000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
46838000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9707000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
108000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
137000
CY2021Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1070000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
38504000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8738000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3706000
CY2020Q2 awh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5059000
CY2020Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
320000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7267000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4287000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
508000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
61000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-262000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
269000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5302000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3831000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
295000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
122000
CY2020Q3 awh Common Stock And Warrants Issued In Conjunction With Private Placement Sale Net Of Issuance Costs
CommonStockAndWarrantsIssuedInConjunctionWithPrivatePlacementSaleNetOfIssuanceCosts
10652000
CY2020Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
349000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
14550000
us-gaap Net Income Loss
NetIncomeLoss
-22701000
us-gaap Net Income Loss
NetIncomeLoss
-11824000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
35000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
10000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
238000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
178000
us-gaap Share Based Compensation
ShareBasedCompensation
2949000
us-gaap Share Based Compensation
ShareBasedCompensation
1121000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
awh Forgiveness Of Paycheck Protection Program Loan
ForgivenessOfPaycheckProtectionProgramLoan
1006000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
238000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-76000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-248000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
107000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
20000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
821000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
230000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19746000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9978000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
154000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
267000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-154000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-267000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
148000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
143000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
679000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
804000
awh Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
1006000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5059000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10652000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48236000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
378000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48389000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17378000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28489000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7133000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16631000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11703000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45120000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18836000
us-gaap Interest Paid Net
InterestPaidNet
57000
us-gaap Interest Paid Net
InterestPaidNet
27000
awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
-45000
awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
369000
awh Net Changes In Accounts Payable Related To Capital Expenditures
NetChangesInAccountsPayableRelatedToCapitalExpenditures
154000
awh Minimum Percentage Reduction Of False Elevations By Ova1plus
MinimumPercentageReductionOfFalseElevationsByOva1plus
0.40
awh Number Of Technology Transfer Agreements
NumberOfTechnologyTransferAgreements
4
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-462767000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
2968000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
4122000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
200000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
645000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2768000
CY2021Q3 us-gaap Contractual Obligation
ContractualObligation
2984000
CY2021Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
51000
CY2021Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
204000
CY2021Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
406000
CY2021Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
452000
CY2021Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
461000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3477000
CY2021Q3 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
1410000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
22000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
95000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
106000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
116000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
124000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
64000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
527000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
105000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
422000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0934

Files In Submission

Name View Source Status
0000926617-21-000079-index-headers.html Edgar Link pending
0000926617-21-000079-index.html Edgar Link pending
0000926617-21-000079.txt Edgar Link pending
0000926617-21-000079-xbrl.zip Edgar Link pending
awh-20210930.xsd Edgar Link pending
awh-20210930x10q.htm Edgar Link pending
awh-20210930x10q_htm.xml Edgar Link completed
awh-20210930xex31_1.htm Edgar Link pending
awh-20210930xex31_2.htm Edgar Link pending
awh-20210930xex32_1.htm Edgar Link pending
awh-20210930_cal.xml Edgar Link unprocessable
awh-20210930_def.xml Edgar Link unprocessable
awh-20210930_lab.xml Edgar Link unprocessable
awh-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending